Effects of dexmedetomidine and sevoflurane on optic nerve sheath diameter and postoperative nausea and vomiting in patients undergoing microvascular decompression: a retrospective cohort study

右美托咪定和七氟醚对接受显微血管减压术患者视神经鞘直径及术后恶心呕吐的影响:一项回顾性队列研究

阅读:1

Abstract

BACKGROUND: Observe the effects of dexmedetomidine(Dex) and sevoflurane(Sev) on the optic nerve sheath diameter(ONSD) in patients undergoing microvascular decompression (MVD). Find the most appropriate anesthetic maintenance medication scheme to reduce intracranial pressure (ICP)fluctuation and reduce the incidence of adverse reactions such as postoperative nausea and vomiting(PONV). METHODS: In this retrospective cohort study, 90 patients undergoing elective MVD surgery were allocated into Groups P, D, and S. Maintenance of anaesthesia: Group P propofol(Propo) 4-12mg/(kg.h) + remifentanil 0.1-0.2ug/(kg.min); Group D Dex 0.4ug/(kg. h) + Propo 4-12mg/(kg.h) + remifentanil 0.1-0.2ug/(kg.min); Group S 1-2% Sev + Propo 4-12mg/(kg.h) + remifentanil 0.1-0.2ug/(kg.min). The changes in ultrasound-measured ONSD relative to baseline and the occurrence of PONV at different time periods under different anaesthetic maintenance regimens were compared. RESULTS: (1) ONSD values increased significantly from T1 (10 min after tracheal intubation) to T6 (on leaving the post-anaesthesia care unit (PACU)), compared with the same group at T0 (5 min before anaesthesia). ONSD values at each time point of T1-T6, were the lowest in the Group D and the highest in the Group S.(2)In this study, the incidence of PONV within 24 h after MVD was 38.9%, with the lowest in Group D and the highest in Group S. (3) T2 (10 min after lying on side in forward neck flexion)ONSD, T6 (on leaving the PACU)ONSD, the usage of Sev and Dex were associated with PONV, whereas the usage of 0.4ug/(kg.h) Dex was a protective factor. CONCLUSIONS: Dex has a lower effect on ONSD of MVD during the perioperative phase than Sev, and it can, to a certain extent, reduce the fluctuation of ICP. Dex lowers the incidence of PONV within 24 h after MVD and acts as a protective factor for PONV. TRIAL REGISTRATION: The protocol of this study was registered at www.chictr.org.cn (07/02/2024,ChiCTR MR-50-24-010856).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。